Comparison of Efficacy and Safety of Insulin Detemir Once or Twice Daily in a Basal-Bolus Regimen With Insulin Aspart in Patients With Type 1 Diabetes.
Phase of Trial: Phase IV
Latest Information Update: 01 Feb 2017
At a glance
- Drugs Insulin detemir (Primary) ; Insulin aspart
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Acronyms ADAPT
- Sponsors Novo Nordisk
- 31 Aug 2018 Biomarkers information updated
- 07 Jul 2009 Actual end date (Oct 2006) added as reported by ClinicalTrials.gov.
- 08 Apr 2009 Additional lead trial centre and investigator identified as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History